Lilly Announces Leadership, Business Unit Changes
(photo courtesy: Eli Lilly & Co.)
Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowIndianapolis-based Eli Lilly and Co. (NYSE: LLY) has announced executive leadership changes and the creation of neuroscience and immunology business units. Lilly says the changes will increase its focus on introducing breakthrough new medicines to people with unmet needs.
Beginning September 5, Lilly Bio-Medicines will split into two business units: Lilly Neuroscience and Lilly Immunology.
Anne White, currently senior vice president and president of Lilly Oncology, will lead Lilly Neuroscience as senior vice president and president. White will be responsible for Lilly’s launched products and Phase 3 portfolio in pain and neurodegeneration, including the potential launch of donanemab for the treatment of Alzheimer’s disease.
“As we prepare for an exciting period of growth and the potential launch of new breakthrough medicines over the next few years, these leadership and organizational changes will allow us to realize the many opportunities we have to improve the lives of people around the world,” said David Ricks, Lilly’s chairman and chief executive officer. “Anne, Jake and Patrik’s extensive experience will bring the focus and agility necessary to lead the growth of our existing medicines and the global introduction of Lilly’s late-stage pipeline for the benefit of patients across a diverse set of medical conditions.”
Jacob Van Naarden, chief executive officer of Loxo Oncology at Lilly, will add the roles of senior vice president at Loxo Oncology and president of Lilly Oncology. The company says he will unify both organizations and serve on Lilly’s executive committee.
Patrick Jonsson has been named president of Lilly Immunology, in addition to his roles as senior vice president and president of Lilly USA and chief customer officer. The company says in his new role, Jonsson will lead Lilly’s launched products and Phase 3 portfolio of medicines in dermatology, gastroenterology and rheumatology.
Additionally, Lilly International President Alfonso Zulueta will retire from the company at the end of the year. Lilly Bio-Medicines President Ilya Yuffa has been named as Zulueta’s successor.
“Chito’s contributions have had a profound impact on our company. His legacy is grounded in his unwavering commitment to patients, development of industry-leading commercial capabilities and mentorship of countless leaders,” said Ricks. “Ilya’s breadth of experience and devotion to excellence makes him uniquely qualified to lead our growing international business and support the launch of new medicines around the world.”
The company says Mike Mason will continue to serve as senior vice president and president of Lilly Diabetes.